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outpatient Administration
I of Paclitaxel
f

Oncology
Siu-Fun Wong, Pharm.D., FCSHP

r
Introduction

Recent review of the published phase
paclitaxel (Taxol®, Bristol-Meyers I trials of paclitaxel suggests that the adSquibb), anti neoplastic agent made from ministration of premedications may play
the bark of the Pacific yew tree, is un- a more important role in reducing the
doubted ly one of the most exciting agents occurrence of severe hypersensitivity reto be evaluated over the past decade. action than the dosing schedule itself.
paclitaxel has demonstrated significant This observation is supported by a large
promise against ovarian and metastatic randomized trial which compared two
breast cancer, and appears to be the most .,_doses of paclitaxel (175 and 135 mg/m 2)
effective single agent to date for non- and two schedules (24 and three hours)
small-cell lung cancer in trials conducted using a bifactorial design. The incidence
by Eastern Cooperative Oncology Group of severe hypersensitivity reactions was
(ECOG).
1 .2% with the longer infusion and 2.2%
The toxicities of paclitaxel include
myelosuppression, neuropathy, cardiac
arrhythmias, and hypersensitivity reactions. Based on initial observations suggesting that the incidence of hypersensitivity reactions may be higher with the
shorter infusion durations, later trials were
developed using 24-hour infusions and
prophylactic antiallergic regimens. Using this method of administration, which
generally requires an inpatient hospital
admission, the incidence of hypersensitivity reactions was approximately 3%.
In this article, we will examine the
results of ongoing trials using a shorter
three-hour infusion time of paclitaxel given at various doses and focus on the issues
of dosing and safety, efficacy, and method of administration thus alleviating the
need for inpatient hospital admission and
thereby maximizing the cost effectiveness of this drug therapy.

Dosing and Safety
Severe hypersensitivity reactions were
identified early in the course of phase I
clinical trials of paclitaxel; the majority
occurred in association with a short infusiontimeof paclitaxel (one to three hours).
As a result of these observations, the
length of administration was increased
and a premedication regimen that included steroids and hl and h2 histaminereceptor blockers was introduced. Subsequent studies proved that these results
Were safe.

Paclitaxel has
de1nonstrated
significant prornise
against ovarian
and nietastatic
breast cancer, and
appears to be tl:Je
rnost effective
single agent to date
for non-sniall-cell
lung cancer.

with the shorter one. Of note, there also
was no apparent effect of dose on the
occurrence of severe hypersensitivity reactions in this trial (1.4% with the higher
dose, 1.9% with the lower).
A recent study by Schiller et al demonstrated that higher paclitaxel doses up to
300 mg/m 2 can be administered over

three hours with the standard
premedications. One of 35 patients (2.8%)
had a grade 3 anaphylactic reaction within one minute of initiation of his second
dose of 250 mg/m 2 of paclitaxel requiring
treatment with diphenhydramine, fluids,
and oxygen. Rechallenge was not conducted. Another patient developed facial
flushing and severe headaches approximately 15 minutes following completion
of his first cycle of 300 mg/m 2 of paclitaxel.
No treatment was given, and the patient
received subsequent courses of pad itaxel
at the same dose without any recurrence
of the symptoms. The author concluded
that with proper monitoring and pre-medication, high doses of paclitaxel can be
safely administered in the outpatient setting.
More studies are currently being conducted to evaluate one-hour infusion of
paclitaxel in combination with other
antineoplastic agents, and the preliminary reports were published in the proceedings of the 1994 Annual Meeting of
the American Society of Clinical
Oncology.
The effects of paclitaxel on the bone
marrow, however, are dose related. lnteresti ng ly, the previously mentioned
bifactorial randomized trial demonstrated striking decreases in bone marrow
suppression associated with the threehour paclitaxel infusion. The short infusion was associated with a 17% incidence of grade 4 granulocytopenia and
no febrile neutropenia, whereas 74% of
the patients given pacl itaxel over 24 hours
developed grade4 granulocytopenia and
12% febrile neutropenia. Pharmacokinetic data indicated both area-under the
curve (AUC) and Cmax values to be substantially higher when identical doses of
paclitaxel are administered over three
pours as compared to 24 hours. However,
the percentage decreases in both the white
blood cell counts and the absolute neutrophil counts follows an Emax model
that relates these parameters to the dura-
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tion that the plasma concentration of
paclitaxel is maintained about 0.1 umol/

L.
Drug sequencing also plays a significant role in toxicities when 24-hour infusion of paclitaxel is combined with
cisplatin or doxorubicin. Increased
neutropenia and decreased paclitaxel
clearance are observed when cisplatin is
administered before paclitaxel regardless
of dose. The potential mechanism is the
inhibition of cytochrome P-450 dependent paclitaxel metabolizing enzyme by
cisplati n. Cumulative thrombo-cytopenia,
infections, and severe mucositis become
the dose Iimiting toxicities when pacl itaxel
125 mg/m 2 24-hour infusion precedes.,_
doxorubicin 48 mg/m 2 48-hour infusion;
when the sequence is reversed, the doses
of both agents can be escalated. Doxorubicin level was also noted to increase by
30% when paclitaxel was administered
prior to doxorubicin.
Many combination regiments using
one-hour and three-hour paclitaxel infusion in various diseases are currently undergoing evaluation and were reported at
the 1994 Annual Meeting of the American Society of Clinical Oncology. The
effect of drug sequencing was not studied
in these preliminary reports, but it is speculated that this effect in the three-hour
infusion is probably less significant due to
the overlapping kinetic factors.
Peripheral sensory neuropathy can also
occur with paclitaxel and is dose related
but not scheduled related. Arthralgias and
myalgias sometimes occur in association
with peripheral neuropathy. Schiller's
report suggested that troublesome
arthralgias and myalgias are more prominent with high doses (>250 mg/m 2 ) administered over three hours in comparison with similar doses over 24 hours and
lower doses (210 mg/m 2 ) overthree hours.
In this study, 27 of 111 courses (24%)
required narcotics for pain control.
Prednisone also appeared to promptly
alleviate the symptoms of many of these
patients.
Other side effects, such as nausea/
vomiting, mucositis, and diarrhea seen
with paclitaxel administration are more
associated with dosing than with schedule effects.

Efficacy
The key question surrounding both the
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Table 1.

Manifestations and Recommended Management of
Hypersensitivity Reaction Associated with Paclitaxel Infusion
Major manifestations:
Other manifestations:
Recommended
premedications:
Recommended
precautions:

Recommended
treatment:

Respiratory distress + bronchospasm, hypotension,
angioedema
• Flushing, urticaria, rashes, chest and extremity pains

•

• Dexamethasone 20 mg IV or PO at -12 and -6 hour
• Diphenhydramine 50 mg IV at -30 min
• Cimetidine 300 mg or ranitidine 50 mg IV at -30 min
• Medical personnel should be available (especially for
the first two treatments)
• Emergency equipment, fluids, pressors, and other
injectable drugs (e.g., epinephrine, diphenhydramine,
steroids) close to bedside
Major manifestations:

•
•
•
•

discontinue paclitaxel immediately
diphenhydramine 25-50 mg IV as indicated
pressors, fluids, epinephrine as indicated
dexamethasone 20 mg IV every 6 hours for persistent
symptoms

Minor manifestations:

" diphenhydramine 50 mg IV every 4 to 6 hours as
indicated
• symptomatic treatment

Recommended
rechallenge:

• Dexamethasone 20 mg IV every 6 hours for 4 doses
(may begin as soon as patient is stabilized); the last
dose should be given 30 mins before the rechallenge
• Diphenhydramine 50 mg IV and cimetidine 300 mg or
ranitidine 50 mg IV 30 mins before the rechallenge·
• A freshly prepared solution of paclitaxel should be
given at 10% of the rate required to deliver the solution
over 24 hrs; this rate should be maintained for 2 hours.
If no major reaction occurs, the rate should be increased gradually over the next 6 hours to the original
24-hour rate. If the original HSR occurred after a
negligible dose of paclitaxel, the full does should be
readministered. If a substantial fraction of the dose was
infused before the HSR, the rechallenge dose should be
the remaining dose fraction. Medical personnel should
be available.

dose and the schedule issues of paclitaxel
is the effect on antitumor efficacy. At the
present time, efficacy data comparing
different infusion durations are available
from only one clinical trial. National Cancer Institute of Canada (NCIC)/European
investigators randomized patients with
platinum-pre-treated ovarian cancer in a
2x2 factorial design to one of two doses of
paclitaxel, 135 and 175 mg/m 2 , and one
of two infusion durations, three or 24
hours. Neither response rates (17% vs
20%) nor survival rates differed for patients on the three- and 24-hour arms.
However, the 24-hour schedule was associated with substantially more grade 4

neutropenia (7 4% vs 17%) and a higher
incidence of febrile neutropenia (12% vs
0%). Thus, only 76.5% of patients in the
24-hour group received at least 90% of
the planned dose as compared with 92%
in the three-hour arm.
One question which needs to be addressed is whether the support of granulocyte colony-stimulating factor(G-CSF) will
allow maintenance of chemotherapy
dose-intensity of the 24-hour arm. The
Gynecology Oncology Group (COG) is
currently conducting a randomized phase
Ill trial in ovarian cancer addressing the
role of G-CSF with a 24-hour infusion of
high dose paclitaxel (250 mg/m 2 ) with the
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~~~~ercially Available Administration Sets for Delivery of Paclitaxel
/. Institutional Administration

catalog Number

Type of Pump

Description

ABBOTT (1-800-222-6883)
Omni-Flow
11140-48
Proximal set
4000 series
(container to pump) +
Distal extension set
1736-48
· (pump to patient)
Vented dual channel set · Lifecare 5000 plus
2427-02
Vented set
Lifecare Macro
1772-01
(flow rate 999ml/hr)
Lifecare Macro
Vented set
9252-68
(flow rate 99.9ml/hr)
BAXTER (1-800-933-0303)
..,_
2C1042
Vented Set
1(8355S
Vented with in-line filter

Flo-Guard 8000 series
Flo-Guard 6000 series

!MED (1-800-854-2033)
2260
2262
2264

Vented Set
Non-vented set
Vented set with
in-line filter
Vented set
Non-vented set

Gemini PC 1 & 2
Gemini PC 1 & 2
Gemini PC 1 & 2

Vented & non-vented set
+ extension set 14" with
in-line filter

IVAC 590 & 599 model

9630
9635
JVAC (1-800-854-7128)
59953
C20350

IMED 900 model
IMED 900 model

MCGAW (1-800-854-6851)
V8333
Vented & non-vented set

AccuPro pump

II. Ambulatory Infusion Pump

ABBOTT
Pancretec Provider 5000
Pump

McGaw Excel 250, 500, or 1000 ml polyolefin container
+ Abbott/McGaw adaptor (#11075) +Abbott Lifeshield
Anesthesia Pump set-OL polyethylene-lined cartridgetubing set (#13503) + IVEX-HP in-line filter (#4524)

BLOCK (1-800-944-1501)
Verifuse Ambulatory
McGaw Excel polyolefin container+ Block vented
(V021011) or non-vented set (V021014) with 0.22
Infusion Pump
micron filter or
Reservoir set (V021012) Non-PVC 120 ml container
+tubing set

=

PHARMACIA DEL TAC (1-800-426-2448)
CADD-1, CADD-PLUS,
McGaw Excel polyolefin container+ TOTM remote
CADD-PCA
reservoir adaptor cassette (#21-7016) [bag spike and 60inch tubing included]**
III. Filters for Administration of Paclitaxe/

Catalog Number

Description

Type of Pump

Abbott 4524-58
Abbott 4521-48
Abbott 2679-48

IVEX-HP
IV EX-HP
IVEX-2

various
various
various

**in-line filter not included in the current product, may add filter at the end of tubing
but non-luer-lock system.needs to be taken into consideration if patient is to receive
treatment at home

secondary goal to evaluate the dose of the
cytokine required. Other trials in patients
with breast and lung cancer are ongoing
to address the efficacy of higher doses of
paclitaxel with or without G-CSF and
determine the impact of different administration schedules on therapeutic outcomes. Although in-vitro data indicated
that one-third activity was recorded with
three-hour exposure time vs. 24-hour
exposure time, in previously treated ovarian and breast cancer patients, the endpoint of the treatment is primarily palliative which makes the toxicities of the
therapy, cost of treatment and the quality.
of life of the patients far outweigh the
potential differences in the response rate.

Method of Administration
Because of the unique nature of
paclitaxel, with its complicated formulation and potentially significant side effects, special preparation of the pacl itaxel
infusion and monitoring of patients are
required.
Hypersensitivity reactions, particularly anaphylactoid signs and symptoms, are
a major concern during paclitaxel administration. The majority of the hypersensitivity reactions are reported to occurwithin
5-10 minutes of the initiation of infusion
and during the first and second doses of
paclitaxel. The manifestations and recommended management are listed in
Table 1. For outpatient administration of
paclitaxel over three hours, a test dose or
close monitoring with recommended premedications is being used.
Prior to the availability of Dr. Schiller's
report, three patients at our institution (11
courses) were treated with high dose
paclitaxel (250 mg/m 2) infused over six
hours in the outpatient infusion center.
Al I patients were pre-treated with standard antiallergic medications and did not
receive a test dose. All three patients
tolerated their therapy without any complications.
Another consideration is the interaction of the drug with the administration
device. Paclitaxel is poorly soluble and
requires a vehicle containing
polyoxyethylated castor oil (Cremophor
EL) which is known to leach phthalate
plasticizers (e.g., diethlhexylphthalate
[DEHP]) from polyvinylchloride (PVC)
bags and administration sets. Glass or
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polyolefin containers are recommended
for preparation of the solution. Non-PVC
(e.g., polyethylene-lined) tubing sets with
an in-line 0.2 micron filter are also recommended by the National Cancer Institute. Table 2 lists the current commercially available administration sets for deliv·ery of paclitaxel in an institutional setting
or via ambulatory infusion pump.
Current stability data indicates thatthe
drug remains chemically and physically
stable for 48 hours at 0.3 - 1 .2 mg/ml at
room temperature and normal fluorescent light. For a three-hour infusion, most
of the solution can be diluted in 300- 500
ml 0.9% sodium chloride or 5% dextrose.
··-Compatibility information of paclitaxel
solutions with other medications is minimal. A recent study was published by
Trissel and Martinez on turbidimetric assessment of the compatibility of Taxol®
with 42 other drugs during a simulated Ysite injection. The combination of
paclitaxel with four drugs, including
chlorpromazine, hydroxyzine, methylprednisolone and mitoxantrone, resulted
in decreases in the inherent surfacant
haze from the Taxol® formulation. This
loss may indicate an interaction between
the drugs and the formulation. Combination with amphotericin B resulted in an
increase in turbidity which eventually
under went separation and layering.
Chemical stability of the drug combinations mentioned above were not conducted in this study.
Local venous effects can also occur
with administration of pad itaxel. Tenderness, darkening and hardness can sometimes be noted several inches above an
intravenous site through which the drug
has been infused. These effects tend to be
delayed, sometimes becoming apparent
one to three weeks after treatment, and
can last indefinitely. Clinical data with
paclitaxel extravasation appears to cause
minimal long-term effects, although patients can experience pain, edema, and
erythema at the site fol lowed by a brawny
(rough) appearance of the skin.
In a recent report where pad itaxel 250
mg/m 2 was infused through peripheral
intravenous access over 24 hours, three
out of 24 patients developed grade 2
severity skin reactions based on the Common Toxicity Criteria developed by the
NCI. In one patient, histopathologic evi-

dence of marked soft-tissue necrosis w
)
documented. This report suggested tha~
paclitaxel is a vesicant and that the seve~~
ity of the soft-tissue injury should be clas.
}
sified as moderate. Additionally, this
dr.ug also appears to cause delayed soft.
tissue reactions such as those that have
been observed with vinblastine. All pa.
tients receiving paclitaxel should be rnon. i
itored for extravasation.
In
Treatment options for paclitaxel
extravasation are not well documented
rn<
and the role of hyaluronidase is unknown'.
rac
A protocol presently used by The Johns
to
Hopkins Oncology Center recommends
rn<
close observation and minimization of
ice:
the amount of drug extravasated by aspiration before removing the intravenous
fie
catheter. Following removal of the cathci2
eter, warm compresses are applied to the
thE
extravasation site for 24 hours. lntraderOU
mal infiltration of the site with normal
tOf
saline to dilute paclitaxel in the tissue
bu
does not appear to increase effectiveness.
an1
There is no data available to indicate any
ffiE
difference inthe incidenceofextravasation
rm
between the three-hour and the 24-hour
die
infusions.
ic,
for
Conclusion
sci
Current data indicates that a threehour infusion of high-dose paclitaxel is
Th
safe, well-tolerated and does not result in
a higher incidence of hypersensitivity rein1
actions than the 24-hour infusion. No
be1
unexpected side effects or toxicities were
thE
observed, with the possible exception of
to
arthralgias and myalgias. If proper
da1
premedications and monitoring are proan1
vided, paclitaxel can be safely adminisstu
tered via a shorter infusion time in an
dn
outpatient setting, resulting in considerbe
able cost savings and improvement in
mE
convenience for patients.
•
Dr. Wong is an Oncology Pharmacist
Specialist at the University of California I •
Irvine Medical Center in Orange.
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Editor's Note: References are available
upon request.
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